Neoadjuvant, Adjuvant, or Both? Optimizing Perioperative Systemic Therapy in Lung Cancer

Area of Science:

• Oncology
• Thoracic Surgery
• Pharmacology

Background:

• Adjuvant chemotherapy alone has limitations in treating resectable non-small cell lung cancer.
• There is a need for more effective perioperative treatment strategies.

Purpose of the Study:

• To review the evolving landscape of perioperative systemic therapy for resectable non-small cell lung cancer.
• To discuss the integration of novel therapies and biomarker-guided approaches.

Main Methods:

• Literature review of perioperative systemic therapy in non-small cell lung cancer.
• Discussion of adjuvant and neoadjuvant treatment settings.
• Analysis of targeted therapies and immune checkpoint inhibitors.

Main Results:

• Novel perioperative therapies demonstrate survival benefits.
• Biomarker-guided approaches are crucial for personalized treatment.
• Individualized and multidisciplinary strategies are essential.

Conclusions:

• Perioperative systemic therapy significantly improves outcomes for resectable non-small cell lung cancer.
• Optimal sequencing of novel agents is key.
• Future directions involve further refining personalized treatment plans.